Boosting the Body's defenses: new drug aims to help lung cancer patients tolerate tough treatment
NCT ID NCT06139419
Summary
This study is testing if adding a drug called thymosin alpha 1 helps people with a specific type of advanced lung cancer complete a full year of follow-up immunotherapy. The immunotherapy is given after initial chemotherapy and radiation. Researchers will compare two groups of patients to see if the drug improves survival, reduces side effects, and helps more people finish the planned treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun yat-sen university cancer center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.